Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
NCT01456195 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
- Lead sponsor
- Takeda
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2011
- Completion date
- July 31, 2013
- Enrollment
- 421 (actual)
- Sites
- 95
Conditions
As the registry lists them; a condition with its own page is linked.